Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation

Dong, Zengxiang; Yang, Hong; Miao, Zhuangzhuang; Wang, Hao; Xie, Ruiqin; Wang, Ye; Shang, Yingfang; Gong, Chunlin; Liang, Zhaoguang

doi:10.3892/br.2017.896

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 17 of the 58 articles (29%), we noted discrepancies with AF guidelines, specifically regarding the PCV drug used, the patients' comorbidities and the PCV contraindications (Table 4). 16,18,[20][21][22][26][27][28]31,32,36,39,41,49,55,60,63 According to the data presented in the articles, it appeared that a total of 239 patients underwent PCV using a drug that was contraindicated given their specific comorbidities. In the described cases, the most common culprit PCV drug was ibutilide, followed by vernakalant, amiodarone, propafenone, and flecainide.…”

Section: Resultsmentioning

confidence: 99%

“…The most commonly described clinical situation for the use of contraindicated drug was ibutilide when administered to a patient with HF, which is contraindicated according to the ACEP, CAEP and ESC guidelines (Table 2). 10,12,13,31,39,55,63 In 9 of the 17 articles, using a contraindicated drug during PVC was performed in the ED (Table 4). 21,22,26,27,32,36,39,55,63 Due to incomplete data, it was impossible to assess whether an additional 338 patients were administered a PCV drug that was contraindicated or not.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Does the choice of drug in pharmacologic cardioversion correlate with the guidelines? Systematic review

Springer¹,

Szmuda²,

Kozłowski³

2021

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Atrial fibrillation (AF) is the most common sustained arrhythmia, the most common cause of supraventricular tachycardia in the global population and the most common arrhythmia requiring treatment in an emergency department. Objectives.To systematically review recent literature and quantify the correlation between the choice of pharmacological cardioversion (PCV) drug and the national or international guidelines. Materials and methods.A systematic review was performed in accordance with the PRISMA statement methodology. The PubMed search engine was used to search for articles regardless of type or language and published in the last 6 years (May 2014-May 2020). In addition, we searched for AF guidelines and recommendations published online by cardiology and emergency medicine societies.Results. The search strategy returned a total of 2615 abstracts. A total of 2598 full texts were screened; 2540 full texts were excluded with reasons and 58 articles from 32 countries were included in the analysis. In 17 of the 58 articles (29%), we noted discrepancies with the AF guidelines, specifically regarding the PCV drug used, the patients' comorbidities and the contraindications associated with the PCV drug. The most common clinical situation for the use of a contraindicated drug was when ibutilide was administered to patients with heart failure. The analysis did not reveal any statistically significant correlations, although the correlation between the sample size and guideline adherence was close to statistical significance (p < 0.06). Conclusions.Our systematic analysis revealed substantial non-adherence to AF treatment guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Does the choice of drug in pharmacologic cardioversion correlate with the guidelines? Systematic review

Springer¹,

Szmuda²,

Kozłowski³

2021

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…The mean age was found 64±11 years and 67±8 years by Connolly et al 18 and Kowey et al 19 respectively. Dong et al 20 reported seventy nine consecutive patients (48 males and 31 females; mean age, 64.6±11.2 years; range, 40-80 years). Boutitie et al 15 showed in their study that the mean age was 60.7±10.7 years and 84.4% were male.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of amiodarone in the treatment of ventricular arrhythmias in patients with coronary artery disease in Bangladesh

et al. 2021

View full text Add to dashboard Cite

Background: Ventricular arrhythmias (VA) are among the most feared complications of coronary artery disease (CAD) and one of the major contributors of death in CAD patients. Antiarrhythmic drug (AAD) therapy is required for recurrent significant VA in the absence of need for further revascularization. But all AADs do not have the same efficacy against life threatening VA and supraventricular arrhythmias (SVAs). Methodology: All (50) patients admitted in the department of Cardiology, BSMMU with ventricular arrhythmias with CAD fulfilling the inclusion and exclusion criteria were included in the study. Informed written consent was taken from each patient before enrollment. Detailed history was taken and relevant physical examinations were done. Loading dose followed by maintenance dose of amiodarone was given and recorded. Relevant lab investigations were performed and recorded in predesigned semi-structured data collection sheet. Symptomatic improvement was assessed, relevant physical examination was done and lab investigations were performed at 1, 3 and 6 month follow up. After editing data analysis was carried out by using the Statistical Package for Social Science (SPSS) version 23.0 windows software. Results: The mean age was found 57.7±8.0 years with a range of 45 to 78 years. Almost two third (62.0%) patients were male and 19(38.0%) patients were female. Male female ratio was 1.6:1. Almost three fourth (74.0%) patients had chest pain, 15(30.0%) had palpitation and 11(22.0%) had shortness of breath. Two third (66.0%) patients had hypertension, 23(46.0%) had dyslipidemia, 17(34.0%) had smoking and 9(18.0%) had diabetes mellitus. Twenty nine (58.0%) patients had family history of IHD. The difference was statistically significant (p<0.05) when compared to baseline. Regarding arrhythmia, 45(90.0%) patients was found to have PVC in baseline and 3(6.4%) at 6th month. The reduction of PVC and VT at six month were statistically significant (p<0.05) when compared to baseline. Regarding outcome 2(4.1%) patients died, one patient dropped out due to thyroid dysfunction and 47 were alive. Conclusion: In conclusion it was found that different forms of ventricular arrhythmias like PVCs, VT were significantly reduced gradually with amiodarone therapy at 6th month follow up. J Dhaka Medical College, Vol. 29, No.2, October, 2020, Page 158-164

show abstract

“…Hypotension was the major adverse event seen with procainamide 58 . In a relatively recent report, pretreatment with intravenous amiodarone increased success rates of cardioversion with intravenous ibutilide 59 …”

Section: Introductionmentioning

confidence: 98%

Cardioversion of recent‐onset atrial fibrillation using intravenous antiarrhythmics: A European perspective

Lévy

2021

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Pharmacological cardioversion using intravenous antiarrhythmic agents is commonly indicated in symptomatic patients with recent‐onset atrial fibrillation (AF). Except in hemodynamically unstable patients who require emergency direct current electrical cardioversion, for the majority of hemodynamically stable patients, pharmacological cardioversion represents a valid option and requires the clinician to be familiar with the properties and use of antiarrhythmic agents. The main characteristics of selected intravenous antiarrhythmic agents for conversion of recent‐onset AF, the reported success rates, and possible adverse events are discussed. Among intravenous antiarrhythmics, flecainide, propafenone, amiodarone, sotalol, dofetilide, ibutilide, and vernakalant are commonly used. Antazoline, an old antihistaminic agent with antiarrhythmic properties was also reported to give encouraging results in Poland. Intravenous flecainide and propafenone are the only Class I agents still recommended by recent guidelines. Intravenous new Class III agents as dofetilide and ibutilide have high and rapid efficacy in converting AF to sinus rhythm but require strict surveillance with electrocardiogram (ECG) monitoring during and after intravenous administration because of the potential risk of QT prolongation and Torsades de Pointes, which can be prevented and properly managed. Vernakalant, a partial atrial selective was shown to have a high success rate and to be safe in real‐life use.

show abstract

Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation

Cited by 4 publications

References 21 publications

Does the choice of drug in pharmacologic cardioversion correlate with the guidelines? Systematic review

Does the choice of drug in pharmacologic cardioversion correlate with the guidelines? Systematic review

Efficacy of amiodarone in the treatment of ventricular arrhythmias in patients with coronary artery disease in Bangladesh

Cardioversion of recent‐onset atrial fibrillation using intravenous antiarrhythmics: A European perspective

Contact Info

Product

Resources

About